Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT01333540
PHASE2
A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation
Sponsor: Glycyx Therapeutics
View on ClinicalTrials.gov
Summary
A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD-1211 in Subjects With Opioid-Induced Constipation
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2011-05
Completion Date
2012-06
Last Updated
2026-05-22
Healthy Volunteers
No
Conditions
Interventions
DRUG
TD-1211
Escalating doses
DRUG
Placebo
Placebo once daily
Locations (1)
Clinical Research Unit
Salt Lake City, Utah, United States